東華軟件(002065 .SZ):子公司中標1.99億元項目
格隆匯 12 月 7日丨東華軟件(002065 .SZ)公佈,近日,公司全資子公司北京東華合創科技有限公司收到招標代理機構福建省天海招標有限公司(受福建省數字福建雲計算運營有限公司的委託)發出的《中標通知書》,中標項目金額為人民幣1.99億元,項目名稱及內容:東南健康醫療大數據中心IT基礎設施建設一期工藝施工總集成項目。
此次中標符合公司業務戰略規劃,代表公司在智慧城市的健康醫療大數據方向得到客户及評審專家的高度認可,展現了公司在智慧城市領域的綜合技術實力和行業競爭優勢,本項目的實施將對公司的未來業務發展及經營業績提升產生積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.